TONIX PHARMACEUTICALS HOLDIN (TNXP)
US8902608475 - Common Stock
Taking everything into account, TNXP scores 2 out of 10 in our fundamental rating. TNXP was compared to 568 industry peers in the Biotechnology industry. TNXP may be in some trouble as it scores bad on both profitability and health. TNXP is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
TNXP had negative earnings in the past year.
In the past year TNXP has reported a negative cash flow from operations.
TNXP had negative earnings in each of the past 5 years.
In the past 5 years TNXP always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -142.38%, TNXP is doing worse than 84.07% of the companies in the same industry.
TNXP's Return On Equity of -182.25% is on the low side compared to the rest of the industry. TNXP is outperformed by 67.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -142.38% | ||
| ROE | -182.25% | ||
| ROIC | N/A |
ROA(3y)-55.21%
ROA(5y)-86.34%
ROE(3y)-69.72%
ROE(5y)-119.89%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TNXP has a Gross Margin of 20.74%. This is in the better half of the industry: TNXP outperforms 74.51% of its industry peers.
The Profit Margin and Operating Margin are not available for TNXP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 20.74% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TNXP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TNXP has been reduced compared to 1 year ago.
The number of shares outstanding for TNXP has been increased compared to 5 years ago.
TNXP has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -9.67, we must say that TNXP is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.67, TNXP is doing worse than 72.57% of the companies in the same industry.
A Debt/Equity ratio of 0.07 indicates that TNXP is not too dependend on debt financing.
TNXP has a Debt to Equity ratio of 0.07. This is in the lower half of the industry: TNXP underperforms 63.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.67 |
ROIC/WACCN/A
WACC11.83%
2.3 Liquidity
TNXP has a Current Ratio of 3.33. This indicates that TNXP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.33, TNXP is in line with its industry, outperforming 40.71% of the companies in the same industry.
TNXP has a Quick Ratio of 2.78. This indicates that TNXP is financially healthy and has no problem in meeting its short term obligations.
TNXP's Quick ratio of 2.78 is on the low side compared to the rest of the industry. TNXP is outperformed by 65.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.33 | ||
| Quick Ratio | 2.78 |
3. Growth
3.1 Past
TNXP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 85.35%, which is quite impressive.
Looking at the last year, TNXP shows a very strong growth in Revenue. The Revenue has grown by 182.98%.
EPS 1Y (TTM)85.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.61%
Revenue 1Y (TTM)182.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-29.26%
3.2 Future
TNXP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.92% yearly.
The Revenue is expected to grow by 74.72% on average over the next years. This is a very strong growth
EPS Next Y94.68%
EPS Next 2Y37.32%
EPS Next 3Y25.92%
EPS Next 5YN/A
Revenue Next Year61.45%
Revenue Next 2Y42.72%
Revenue Next 3Y74.72%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
TNXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNXP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TNXP's earnings are expected to grow with 25.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.32%
EPS Next 3Y25.92%
5. Dividend
5.1 Amount
TNXP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TONIX PHARMACEUTICALS HOLDIN
NASDAQ:TNXP (12/20/2024, 8:00:01 PM)
After market: 0.5155 -0.1 (-15.71%)0.6116
+0.04 (+7.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.29%
Inst Owner Change-79.16%
Ins Owners0%
Ins Owner Change0%
Market Cap114.30M
Analysts82.5
Price Target21.42 (3402.29%)
Short Float %0.85%
Short Ratio0.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-192.57%
Min EPS beat(2)-477.45%
Max EPS beat(2)92.31%
EPS beat(4)3
Avg EPS beat(4)-70.42%
Min EPS beat(4)-477.45%
Max EPS beat(4)92.31%
EPS beat(8)5
Avg EPS beat(8)-33.3%
EPS beat(12)7
Avg EPS beat(12)-19.58%
EPS beat(16)8
Avg EPS beat(16)-16.63%
Revenue beat(2)0
Avg Revenue beat(2)-24.21%
Min Revenue beat(2)-38.15%
Max Revenue beat(2)-10.27%
Revenue beat(4)0
Avg Revenue beat(4)-21.93%
Min Revenue beat(4)-38.15%
Max Revenue beat(4)-3.35%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.97%
EPS NQ rev (1m)-89.17%
EPS NQ rev (3m)-89.17%
EPS NY rev (1m)0%
EPS NY rev (3m)5.44%
Revenue NQ rev (1m)-60.92%
Revenue NQ rev (3m)-60.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 10.12 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.54 | ||
| P/tB | 1.54 | ||
| EV/EBITDA | N/A |
EPS(TTM)-52.79
EYN/A
EPS(NY)-31.53
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0.06
BVpS0.4
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -142.38% | ||
| ROE | -182.25% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 20.74% | ||
| FCFM | N/A |
ROA(3y)-55.21%
ROA(5y)-86.34%
ROE(3y)-69.72%
ROE(5y)-119.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 13.19% | ||
| Cap/Sales | 4.89% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.33 | ||
| Quick Ratio | 2.78 | ||
| Altman-Z | -9.67 |
F-Score4
WACC11.83%
ROIC/WACCN/A
Cap/Depr(3y)24885.3%
Cap/Depr(5y)20651.2%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.61%
EPS Next Y94.68%
EPS Next 2Y37.32%
EPS Next 3Y25.92%
EPS Next 5YN/A
Revenue 1Y (TTM)182.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-29.26%
Revenue Next Year61.45%
Revenue Next 2Y42.72%
Revenue Next 3Y74.72%
Revenue Next 5YN/A
EBIT growth 1Y33.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.1%
OCF growth 3YN/A
OCF growth 5YN/A